4D Molecular Therapeutics
Design and develop transformative gene therapy products using our proprietary.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $300m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 144 % | (51 %) | 95 % | 33 % | (83 %) | 562 % | (100 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (69 %) | (565 %) | (406 %) | (395 %) | (3517 %) | (517 %) | (489557 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (68 %) | (706 %) | (416 %) | (395 %) | (3435 %) | (487 %) | (434778 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 130 % | 554 % | 390 % | 340 % | 2565 % | 469 % | 381889 % |
Source: Company filings or news article
Related Content
4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company focused on developing gene therapies. These therapies aim to treat serious genetic diseases by delivering precise genetic material to patients' cells. The company uses a proprietary technology called "Therapeutic Vector Evolution" to create advanced adeno-associated virus (AAV) vectors. These vectors are essentially delivery vehicles that transport therapeutic genes to targeted cells in the body.
4DMT primarily serves patients with genetic disorders, including those suffering from cystic fibrosis and other severe conditions. The company operates in the biopharmaceutical market, which is a highly specialized sector focused on developing new medical treatments using biological methods.
The business model of 4DMT revolves around research and development (R&D) of gene therapies, followed by clinical trials to test their safety and effectiveness. Once these therapies are proven effective, 4DMT aims to commercialize them, either by selling the therapies directly or through partnerships with larger pharmaceutical companies. The company generates revenue through funding agreements, equity investments, and potential future sales of its gene therapies.
Recently, 4DMT raised $75 million in Series C financing, which is a type of funding used to support the company's growth and development. Additionally, they have entered into a new agreement with the Cystic Fibrosis Foundation, securing $14 million in funding to develop a specific gene therapy called 4D-710. This therapy aims to treat cystic fibrosis, a genetic disorder that affects the lungs and digestive system.
In summary, 4DMT is at the forefront of gene therapy innovation, leveraging advanced technology to develop treatments for serious genetic diseases. Their business strategy includes securing funding through investments and partnerships, conducting rigorous clinical trials, and eventually bringing their therapies to market.
Keywords: gene therapy, AAV vectors, genetic diseases, cystic fibrosis, biotechnology, clinical trials, biopharmaceutical, precision medicine, Series C financing, Therapeutic Vector Evolution.